The spliceosome is a dynamic ribonucleoprotein complex containing five small nuclear RNAs (snRNAs: U1, U2, U4, U5, U6) and over 100 proteins that catalyzes pre-mRNA splicing with exquisite precision at conserved splice sites. Splicing is coupled to transcription, occurring as RNA polymerase II elongates; the C-terminal domain of Pol II recruits splicing factors. Alternative splicing (exon skipping, intron retention, alternative 5' or 3' splice sites) allows a single gene to produce multiple protein isoforms, greatly expanding proteomic diversity without increasing genome size.
Isolate and characterize spliceosome assembly intermediates; measure splicing kinetics on defined substrates. Map splice site usage genome-wide using RNA-seq; identify tissue-specific or signal-dependent alternative splicing events.
From your study of RNA splicing mechanisms, you understand that eukaryotic pre-mRNA contains introns that must be removed and exons that must be joined before the mRNA can be translated. The spliceosome is the molecular machine that performs this task — and it is one of the most complex and dynamic assemblies in the cell, rivaling the ribosome in size and sophistication.
The spliceosome is built from five small nuclear ribonucleoprotein particles (snRNPs), each containing one snRNA molecule (U1, U2, U4, U5, or U6) wrapped in a set of proteins. Unlike the ribosome, which exists as a pre-assembled machine, the spliceosome assembles anew on each intron it removes. U1 snRNP recognizes the 5' splice site through base-pairing between its snRNA and the pre-mRNA sequence. U2 snRNP then binds the branch point sequence within the intron, bulging out a critical adenosine residue. The U4/U6·U5 tri-snRNP joins, and a series of dramatic rearrangements follow: U1 and U4 are displaced, allowing U6 to base-pair with the 5' splice site and with U2 to form the catalytic core. It is the RNA components — not the proteins — that catalyze the two transesterification reactions that cut the intron and join the exons, making the spliceosome a ribozyme at heart.
Splicing does not wait until transcription is finished. The spliceosome assembles on the pre-mRNA while RNA polymerase II is still elongating the transcript. The C-terminal domain (CTD) of Pol II — a long, repetitive tail that you encountered in transcription regulation — serves as a landing pad for splicing factors, physically coupling transcription speed to splice site recognition. This has a profound consequence: how fast Pol II transcribes through a region can influence which splice sites are used. A slow polymerase gives weak splice sites more time to be recognized; a fast polymerase may cause them to be skipped.
This coupling enables alternative splicing, the process that allows a single gene to produce multiple distinct mRNA variants and therefore multiple protein isoforms. The human genome has roughly 20,000 protein-coding genes, yet produces over 100,000 distinct proteins — alternative splicing accounts for much of this expansion. The most common form is exon skipping, where a cassette exon is included in some transcripts and excluded in others. Which pattern wins depends on a tug-of-war between splicing enhancers (sequences bound by SR proteins that promote exon inclusion) and splicing silencers (sequences bound by hnRNP proteins that promote exon skipping). Different cell types express different ratios of these regulatory proteins, so the same gene can produce a muscle-specific isoform, a brain-specific isoform, and a liver-specific isoform — all from a single genomic locus.